|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
3.580 +0.140 (+4.070%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| ROAA (%) | 5.426% | 3.653% | 4.083% | 27.114% | 6.541% |
| ROAE (%) | 11.211% | 7.745% | 8.473% | 62.113% | 17.485% |
| Return on Capital Employed (%) | 7.633% | 5.688% | 5.792% | 32.321% | 7.641% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Gross Profit Margin (%) | 81.514% | 80.954% | 79.863% | 80.150% | 78.085% |
| EBITDA Margin (%) | 22.561% | 27.059% | 25.073% | 22.638% | 28.758% |
| Pre-tax Profit Margin (%) | 18.283% | 20.649% | 20.078% | 69.143% | 21.199% |
| Net Profit Margin (%) | 12.124% | 8.901% | 8.838% | 54.384% | 11.718% |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Current Ratio (X) | 1.262 X | 1.053 X | 1.287 X | 1.532 X | 2.083 X |
| Quick Ratio (X) | 1.141 X | 0.965 X | 1.171 X | 1.405 X | 1.911 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Total Liabilities / Total Assets(%) | 34.604% | 39.989% | 40.773% | 37.683% | 52.511% |
| Total Debt / Total Assets (%) | 14.846% | 19.779% | 21.825% | 20.015% | 30.099% |
| Net Debt / Total Assets (%) | 0.216% | 4.918% | 2.990% | 2.558% | 6.250% |
| Total Debt / Shareholders' Funds (%) | 30.383% | 41.281% | 47.003% | 40.004% | 84.849% |
| Long Term Debt / Shareholders' Funds (%) | 6.508% | 4.505% | 14.314% | 18.264% | 75.406% |
| Net Debt / Shareholders' Funds (%) | 0.441% | 10.266% | 6.440% | 5.113% | 17.619% |
| Net Cash / (Debt) ($) | (140.962M) | (3.128B) | (1.916B) | (1.549B) | (2.951B) |
| Net Cash / (Debt) per share ($) | (0.008) | (0.166) | (0.102) | (0.082) | (0.156) |
| Total Debt / Capital Employed (%) | 21.178% | 30.685% | 31.840% | 26.810% | 39.181% |
| Interest Coverage Ratio (X) | 18.883 X | 11.924 X | 14.161 X | 61.180 X | 16.503 X |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Inventory Turnover (Day) | 149.339 Day | 158.085 Day | 134.354 Day | 130.670 Day | 124.617 Day |
| Receivables Turnover (Day) | 59.921 Day | 63.727 Day | 56.176 Day | 48.474 Day | 43.421 Day |
| Payables Turnover (Day) | 17.906 Day | 20.703 Day | 21.119 Day | 24.737 Day | 28.997 Day |
| Remarks: | Real time quote last updated: 11/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,499,834 |
| %Change | 50.083% |
| EPS / (LPS) | RMB 0.191 |
| NBV Per Share (¥) | RMB 1.701 |